Temperature and pH Triggered Insitu Hydrogel of Doxycycline for the Treatment of Chlamydial Conjunctivitis

Author(s)

Patel, D.B., Patel, S.R., Patel, N.K., Patel, M.M.

Author's Affiliation

Abstract

The present investigation describes the formulation and characterization of ophthalmic in situ hydrogel for sustained delivery of doxycycline (DOX) that is frequently used to treat chlymydial conjunctivitis. Insitu hydrogel were prepared using thermo-reversible gelling polymer, Pluronic F 127 (PF127) and PH sensitive and viscosity enhancer polymer Carbopol 940 (CP940). Because of high concentration (20 to 25%w/v) of PF127 polymer required for insitu gelation causes irritation to the eye. So, to reduce this concentration, an attempt was made to combine the PF127 with CP940 showing a pH triggered sol-gel transition by pH of tear fluid. Different batches were prepared of varying concentrations of CP940 (0.1- 0.3%) with PF127 (12%-18%) using DOX 2%w/v. Pluronic F68 (PF68) with 2% and 4% concentration were mixed to obtain a hydrogel with an appropriate gelation temperature. The formulations were optimized by the viscosity measurement and in vitro gelation study. Selected formulations were evaluated for in vitro drug release study using Franz diffusion cell and indicated sustain drug release over a period of 10 h. Stability testing at 80C and 400C and effect of sterilization and were on drug content, pH and clarity were also evaluated. The prepared formulation could reduce not only the concentration of individual polymers but also the side effects without compromising the in vitro gelling capacity. This formulation of Doxycycline insitu hydrogel represents potentially effective ophthalmic delivery system for the treatment of chlaymydial conjunctivitis.

Keywords

Doxycycline, Pluronic F127, Carbopol 940, insitu gelation, simulated tear fluid, Chlamydial conjunctivitis

Cite This Article

Patel, D.B., Patel, M.M., Patel, S.R., Patel, N.K. (2012). Temperature and pH Triggered Insitu Hydrogel of Doxycycline for the Treatment of Chlamydial Conjunctivitis, International Journal for Pharmaceutical Research Scholars (IJPRS), 1(2), 1-7.